Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
On July 24, 2025, Dr. Reddy’s Laboratories announced the re-appointment of Mr. G V Prasad as Co-Chairman and Managing Director for a five-year term starting January 30, 2026. This decision, approved by the shareholders at the company’s 41st AGM, underscores the company’s commitment to leadership continuity and strategic growth, leveraging Mr. Prasad’s extensive experience in the pharmaceutical industry.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The overall stock score of 68 reflects strong financial performance and reasonable valuation, offset by bearish technical indicators. The company’s solid balance sheet and consistent revenue growth bolster its financial health, but short-term market momentum suggests caution.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It is known for its focus on research, innovation, and high standards of corporate governance, offering a range of pharmaceutical products and services globally.
Average Trading Volume: 1,584,757
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.05B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.